- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: anti-hC5aR-32F3A6 GL | IPH-5401 | NN-8210 | NNC-0215-0384
Compound class: Antibody
Comment: Avdoralimab (IPH5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1, and blocks C5a/C5aR1 signalling in subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils. It has immunomodulating activity.
|No information available.|
|Summary of Clinical Use|
|Avdoralimab (IPH5401) has advanced to clinical evaluation as an addition to cancer immunotherapy and for autoimmune diseases.
SARS-CoV-2 and COVID-19: In response to the COVID-19 pandemic, avdoralimab was entered into clinical trial, with the purpose of determining potential efficacy of blocking the C5a-C5aR1 axis to limit myeloid infiltration and prevent excessive lung inflammation in COVID-19 patients .
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT04371367||Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )||Phase 2 Interventional||Assistance Publique Hopitaux De Marseille|
|NCT04563923||Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody||Phase 2 Interventional||Centre Hospitalier Universitaire de Nice|
|NCT03665129||IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors||Phase 1 Interventional||Innate Pharma||In combination with the anti-PD-L1 immune checkpoint anti-cancer agent
|NCT01611688||First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis||Phase 1 Interventional||Novo Nordisk A/S|
|NCT01955603||A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis||Phase 1 Interventional||Novo Nordisk A/S|